LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $127.60 In stock
100 mg $317.50 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • G733409

    GSK-2982772

    RIP1 inhibitor.

    ≥98%
  • E5477

    Entinostat

    Benzamide; HDAC1 inhibitor.

    ≥98%
  • P2997

    Phytic Acid, 40-50 wt% aqueous solution

    Saturated cyclic acid used to store phosphorus ...

    ≥40%
  • D5611

    Docosahexaenoic Acid (all cis-4,7,10,13,16,19) Methyl Ester

    Essential fatty acid found in fish oil, involve...

    ≥99%
  • C3576

    Citreoviridin A

    Mycotoxin; F1F0 ATP synthase inhibitor.

    ≥95%
  • R1806

    Rebamipide

    Quinolone, antioxidant.

    ≥98%
  • U6854

    Urocortin, human

    Endogenous peptide hormone, involved in feeding...

    ≥98%
  • R3312

    Ridaifen A Dihydrochloride

    Tamoxifen derivative; potential proteasome inhi...

    ≥98%
  • M1774

    2-Mercaptoethanesulfonate Sodium

    Organosulfur, antioxidant.

    ≥98%
  • C0374

    β-Casomorphin, human

    Peptide, casein fragment.

    ≥95%
  • N3452

    Nimustine Hydrochloride

    Nitrosourea, DNA cross-linker.

    ≥97%
  • Q8139

    Quizartinib

    FLT3, c-Kit, PDGFR inhibitor.

    ≥98%
  • T1733

    Teicoplanin

    Glycopeptide, vancomycin analog; peptidoglycan ...

    ≥900 ug/mg, bio assay
  • T1644

    Telmisartan

    AT-II antagonist, PPARγ/δ modulator.

    ≥98%
  • T3324

    Tigecycline

    Glycylcycline; protein synthesis inhibitor.

    ≥98%
  • V2792

    VGX-1027

    TLR4 inhibitor.

    ≥98%
  • H1892

    Hexamethylene Bisacetamide

    HEXIM1 activator.

    ≥99%
  • I0480

    Ibudilast

    PDE3/5 inhibitor, LTD4 antagonist.

    ≥98%
  • F1670

    Ferulic Acid Methyl Ester

    Hydroxycinnamic aicd, verbascoside metabolite, ...

    ≥98%
  • G1658

    Gentamycin Sulfate

    Aminoglycoside; protein translation inhibitor.<...